BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35716323)

  • 21. Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferase I activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells.
    Eleftheriadis T; Pissas G; Sounidaki M; Tsogka K; Antoniadis N; Antoniadi G; Liakopoulos V; Stefanidis I
    Int J Mol Med; 2016 Nov; 38(5):1605-1613. PubMed ID: 27667153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the IDO1 pathway in cancer: from bench to bedside.
    Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
    J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.
    Amobi A; Qian F; Lugade AA; Odunsi K
    Adv Exp Med Biol; 2017; 1036():129-144. PubMed ID: 29275469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.
    Curti A; Trabanelli S; Onofri C; Aluigi M; Salvestrini V; Ocadlikova D; Evangelisti C; Rutella S; De Cristofaro R; Ottaviani E; Baccarani M; Lemoli RM
    Haematologica; 2010 Dec; 95(12):2022-30. PubMed ID: 20801903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
    Wainwright DA; Chang AL; Dey M; Balyasnikova IV; Kim CK; Tobias A; Cheng Y; Kim JW; Qiao J; Zhang L; Han Y; Lesniak MS
    Clin Cancer Res; 2014 Oct; 20(20):5290-301. PubMed ID: 24691018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
    Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
    Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. H
    Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
    J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
    Wainwright DA; Balyasnikova IV; Chang AL; Ahmed AU; Moon KS; Auffinger B; Tobias AL; Han Y; Lesniak MS
    Clin Cancer Res; 2012 Nov; 18(22):6110-21. PubMed ID: 22932670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites.
    Terness P; Bauer TM; Röse L; Dufter C; Watzlik A; Simon H; Opelz G
    J Exp Med; 2002 Aug; 196(4):447-57. PubMed ID: 12186837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases.
    Murakami Y; Hoshi M; Imamura Y; Arioka Y; Yamamoto Y; Saito K
    Mediators Inflamm; 2013; 2013():391984. PubMed ID: 23476103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
    Soliman H; Mediavilla-Varela M; Antonia S
    Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
    Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
    Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
    Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
    Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.
    Platten M; Wick W; Van den Eynde BJ
    Cancer Res; 2012 Nov; 72(21):5435-40. PubMed ID: 23090118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
    Engin AB; Engin A
    Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
    Opitz CA; Litzenburger UM; Opitz U; Sahm F; Ochs K; Lutz C; Wick W; Platten M
    PLoS One; 2011; 6(5):e19823. PubMed ID: 21625531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
    Balog A; Lin TA; Maley D; Gullo-Brown J; Kandoussi EH; Zeng J; Hunt JT
    Mol Cancer Ther; 2021 Mar; 20(3):467-476. PubMed ID: 33298590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration.
    Liu XQ; Lu K; Feng LL; Ding M; Gao JM; Ge XL; Wang X
    Leuk Lymphoma; 2014 Feb; 55(2):405-14. PubMed ID: 23682557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review.
    Lin DJ; Ng JCK; Huang L; Robinson M; O'Hara J; Wilson JA; Mellor AL
    Clin Otolaryngol; 2021 Sep; 46(5):919-934. PubMed ID: 34053179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.